Drug-related hypophosphatemia: Descriptive study and case/non-case analysis of the French national pharmacovigilance database

Thillard, Eve-Marie; Sade, Paula; Michot, Joelle; Bres, Virginie; Jonville-Bera, Annie-Pierre

doi:10.1016/j.therap.2023.07.007

Cited by 1 publication

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Severe and life-threatening hypophosphatemia has been more rarely described after intravenous zoledronic acid infusion [ 97 – 99 ] . Likewise, an assessment of serum creatinine and glomerular filtration rate is generally indicated before treatment and thereafter, in case of patient with mild renal impairment, due to the risk of nephropathy [ 100 ].…”

Section: Results and Recommendationsmentioning

confidence: 99%

“…This adverse event is generally mild to moderate in severity and most symptoms generally resolve within 3–7 days after infusion. In a series of PDB cases treated with different intravenous N-BPs, acute phase reaction occurred in up to 50% of naïve PDB patients after the first exposure to the drug, or less frequently (below 15–20%) with subsequent N-BP infusions [ 97 ]. Conversely, concerning gastrointestinal side effects, a Cochrane review did not report any significant difference between PDB patients under oral BP treatment and placebo [ 72 ].…”

Section: Results and Recommendationsmentioning

confidence: 99%

See 1 more Smart Citation

Diagnosis and treatment of Paget’s disease of bone: position paper from the Italian Society of Osteoporosis, Mineral Metabolism and Skeletal Diseases (SIOMMMS)

Rendina,

Falchetti,

Diacinti

et al. 2024

J Endocrinol Invest

View full text Add to dashboard Cite

Introduction Paget’s disease of bone is a focal skeletal disorder causing bone deformities and impairing bone quality. Despite the prevalence of asymptomatic cases is increasing, the progression of the disease can lead to invalidating complications that compromise the quality of life. Doubts on clinical and therapeutic management aspects exist, although beneficial effects of antiresorptive drugs, particularly bisphosphonates are known. However, limited information is available from randomized controlled trials on the prevention of disease complications so that somewhat contrasting positions about treatment indications between expert panels from the main scientific societies of metabolic bone diseases exist. This task force, composed by expert representatives appointed by the Italian Society of Osteoporosis, Mineral Metabolism and Skeletal Diseases and members of the Italian Association of Paget’s disease of bone, felt the necessity for more specific and up to date indications for an early diagnosis and clinical management. Methods Through selected key questions, we propose evidence-based recommendations for the diagnosis and treatment of the disease. In the lack of good evidence to support clear recommendations, available information from the literature together with expert opinion of the panel was used to provide suggestions for the clinical practice. Results and conclusion Description of the evidence quality and support of the strength of the statements was provided on each of the selected key questions. The diagnosis of PDB should be mainly based on symptoms and the typical biochemical and radiological features. While treatment is mandatory to all the symptomatic cases at diagnosis, less evidence is available on treatment indications in asymptomatic as well as in previously treated patients in the presence of biochemical recurrence. However, given the safety and long-term efficacy of potent intravenous bisphosphonates such as zoledronate, a suggestion to treat most if not all cases at the time of diagnosis was released.

show abstract

Section: Results and Recommendationsmentioning

confidence: 99%

Section: Results and Recommendationsmentioning

confidence: 99%